Castle Biosciences (FRA:086) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:086 Castle Biosciences Inc FRA:086
63 GF Score
Price €20.60
GF Value €24.13
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Castle Biosciences FFO per Share?

FFO per Share only applies to REITs.

FRA:086
63GF Score
Castle Biosciences Inc FRA:086
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Castle Biosciences (FRA:086) Overvalued in 2026?

Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued. The current stock price of €20.60 is trading 14.6% below its estimated GF Value™ of €24.13. GuruFocus considers Castle Biosciences to be Modestly Undervalued.

Key valuation signals for FRA:086:

  • FFO per Share:
  • GF Value™: €24.13 vs. price of €20.60 (14.6% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the FRA:086 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Castle Biosciences Business Description

Other Exchanges CSTL:USA
Address 1500 West Parkwood Avenue, Suite 401, Friendswood, TX, USA, 77546
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
63GF Score

Get the complete analysis for FRA:086

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.60
Price
€24.13
GF Value